Dual checkpoint-blockade in urothelial carcinoma—when is it so far
memo - Magazine of European Medical Oncology(2022)
Abstract
Summary Single agent immunotherapy is routinely used in the treatment of localised and advanced bladder cancer. Dual checkpoint inhibition with nivolumab (nivo)–ipilimumab (ipi) and durvalumab (durva)–tremelimumab (treme) shows encouraging activity in phase I/II trials in the neoadjuvant and metastatic disease setting. Several large trials are testing these combinations against the current standard of care. The so far reported results are negative; however, it appears that a subgroup of patients might profit substantially from dual checkpoint blockade. Ongoing trials will elucidate which patients will be candidates for this treatment modality in routine clinical care.
MoreTranslated text
Key words
Dual checkpoint inhibition, Bladder cancer, Nivolumab ipilimumab, Durvalumab tremelimumab, Transition cell carcinoma
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined